UNLOCKED LABS INC.
Biotech · Private
Probiotic strain engineered to biodegrade oxalic acid for prevention of calcium oxalate kidney stones
- Grants
- $2.4M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 5
- 0 granted · 5 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Engineering probiotic yeast to treat hyperuricemia and gout | $244,840 | |
| Federal grant | Department of Health and Human Services · Phase I · Constitutive oxalate-biodegrading Bacillus subtilis for kidney stones | $259,284 | |
| Federal grant | Department of Health and Human Services · Phase I · Constitutive oxalate-biodegrading Bacillus subtilis for kidney stones | $54,965 | |
| Federal grant | Department of Health and Human Services · Phase II · Oxalate Biodegrading Probiotic for Kidney Stone Prevention | $834,533 | |
| Federal grant | Department of Health and Human Services · Phase II · Oxalate Biodegrading Probiotic for Kidney Stone Prevention | $907,860 | |
| Federal grant | Department of Health and Human Services · Phase II · Oxalate Biodegrading Probiotic for Kidney Stone Prevention | $138,861 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2068 | D BioTherapeutics, LLC | — | — |
| 2069 | Isomorphic Labs | — | — |
| 2070 | Courier Therapeutics Inc | — | — |
| 2071 | UNLOCKED LABS INC. | — | — |
| 2072 | Slingshot Biosciences | — | $24M |
| 2073 | ANI Energy, LLC | — | $1.5M |
| 2074 | Key Health Institute of Edmond, LLC | — | $100K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Therapeutic Engineered Microbial Cell Systems and Methods for Treating Conditions in Which Oxalate is Detrimentalapplication
- Therapeutic Engineered Microbial Cell System and Methods for Treating Hyperuricemia and Goutapplication
- Therapeutic Engineered Microbial Cell Systems And Methods For Treating Conditions In Which Oxalate Is Detrimentalapplication
- Therapeutic Engineered Microbial Cell Systems and Methods for Treating Conditions in which Oxalate is Detrimentalapplication
- Therapeutic Engineered Microbial Cell Systems And Methods For Treating Hyperuricemia And Goutapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.